Market Overview

UPDATE: Goldman Sachs Upgrades Myriad Genetics to Buy on Expanded Portfolio, Domestic Bias

Related MYGN
Top 4 NASDAQ Stocks In The Research Services Industry With The Highest EPS
Myriad Genetics Posts Key myPath Melanoma Data - Analyst Blog

Goldman Sachs raises its rating on Myriad Genetics (NASDAQ: MYGN) and raises its price target from $27 to $29.

Goldman Sachs says, "We upgrade shares of MYGN to Buy from Neutral for four reasons: (1) we believe the recent reimbursement concerns are overdone and believe that the patent debate does not pose near/medium term risk; (2) MYGN's highly US-focused business offers several new product catalysts; (3) we see potential for improved capital allocation to drive share outperformance in 2H; and (4) we believe the scarcity value of established Diagnostics assets warrants an M&A premium in our price target methodology."

MYGN closed at $23.77 on Friday.

Posted-In: Goldman SachsAnalyst Color Price Target Initiation Intraday Update Analyst Ratings

 

Most Popular

Related Articles (MYGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free